Ugekommentar: Novo Nordisk er ikke færdig - tværtimod!
-
Novo Nordisk's financial health remains robust despite recent market challenges. The company reported a revenue of $47,399.42 million, with a three-year revenue growth rate of 21.3%. The company's profitability metrics are impressive, with an operating margin of 41.31% and a net margin of 33.14%. These figures indicate a strong ability to convert sales into profits.
-
Tak BS, det er jeg glad for du syntes.
-
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
-
En sådan aftale indgår Novo vel ikke uden en juridisk klokkeklar aftale aftale om at Hims stopper med comoundsalget af GLP1.
-
For en god ordens skyld. Vi mangler at få en officiel bekræftelse på nyheden fra Novo og Hims.
-
Helt og aldeles uenig. Et søgsmål kan trække ud i årevis og gør intet godt for nogen. Der er ingen tvivl om, at hvis aftalen er sand, har Hims givet sig og lagt sig fladt ned. De skal formentlig også kompensere Novo klækkeligt. Novo har overhånden, ikke Hims. Et meget positivt signal er det også, da de vidner om at apotekerne og online distributørene har forstået alvoren fra FDA.
-
En meget glad aktionær i Hims.
-
Novo Nordisk dropper søgsmål mod Hims & Hers og bekræfter partnerskab
https://proinvestor.com/investornyt/1419225/novo-nordisk-dropper-sogsmal-mod-hims-hers-og-bekraefter-partnerskab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind